At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Luis Masana Marín discusses the benefits of PCSK9 inhibitors in clinical practice.
Questions:
1. What is the mechanism of action of Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors? (0:04)
2. What is known about the use of PCSK inhibitors in patients with diabetes? (1:00)
3. What are the limitations of PCSK9 inhibitors? (2:50)
4. Which diabetes patients will benefit most from this class of drug? (3:57)
5. What factors would you consider when deciding whether to prescribe PCSK9 inhibitors to a patient with diabetes? (5:03)
Luis Masana Marín has no conflicts of interest to declare in relation to this video.
Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.
